Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

61.00USD
1:30am IST
Change (% chg)

$-0.20 (-0.33%)
Prev Close
$61.20
Open
$60.85
Day's High
$61.44
Day's Low
$60.50
Volume
3,639,835
Avg. Vol
2,300,089
52-wk High
$71.59
52-wk Low
$45.46

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $99,005.40
Shares Outstanding(Mil.): 1,617.73
Dividend: 0.57
Yield (%): 3.73

Financials

  ABBV.N Industry Sector
P/E (TTM): 18.34 33.80 45.25
EPS (TTM): 3.34 -- --
ROI: -- 13.05 12.52
ROE: -- 13.77 13.42
Search Stocks

AbbVie forges deeper into cancer, as clock ticks for Humira

AbbVie Inc placed another big bet on new cancer drugs on Thursday with a $5.8 billion acquisition that could lessen its dependence on arthritis treatment Humira, the world's top selling drug.

29 Apr 2016

BRIEF-S&P says Abbvie Credit rating lowered to 'A-' from 'A'

* Abbvie Inc. Corp. Credit rating lowered to 'A-' from 'A' on new acquisition plan; stable outlook Source (http://bit.ly/1WteRQW) Further company coverage:

28 Apr 2016

BRIEF-Moody's reviews AbbVie's BAA1 for downgrade

* Action follows the announcement that AbbVie will acquire privately-held Stemcentrx for approximately $5.8 billion in cash and stock

28 Apr 2016

BRIEF-AbbVie says deal gives it strong position in solid tumor drugs

* CEO says Stemcentrx deal will give company long-desired strong position in solid tumors

28 Apr 2016

AbbVie to buy Stemcentrx in $5.8 bln deal

April 28 Drugmaker AbbVie Inc said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.

28 Apr 2016

BRIEF-Abbvie and Cytomx announce strategic collaboration

* Abbvie and cytomx announce strategic collaboration for probody drug conjugates

22 Apr 2016

BRIEF-Argenx and Abbvie to collaborate on ARGX-115 against novel immuno-oncology target

* Argenx and Abbvie to collaborate on ARGX-115 against novel immuno-oncology target

21 Apr 2016

AbbVie gets option on early Argenx cancer drug for $40 million

AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.

21 Apr 2016

AbbVie gets option on early Argenx cancer drug for $40 mln

April 21 AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.

21 Apr 2016

New AbbVie hepatitis C regimen shows high cure rates - studies

An experimental once-daily combination hepatitis C treatment being developed by AbbVie Inc demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product if approved.

16 Apr 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $112.08 -0.40
Pfizer Inc. (PFE.N) $32.71 -0.20
Novartis AG (NOVN.S) CHF73.20 -1.60
Merck & Co., Inc. (MRK.N) $54.84 -0.90
Roche Holding Ltd. (ROG.S) CHF242.50 -4.80
Roche Holding Ltd. (RO.S) CHF245.50 -2.40
Abbott Laboratories (ABT.N) $38.90 -1.52
Eli Lilly and Co (LLY.N) $75.53 -0.93
Sanofi SA (SASY.PA) €72.11 -4.08

Earnings vs. Estimates

Search Stocks